This week, we’d like to direct your attention to two blog posts about Exubera, the inhaled insulin product that was approved by the U.S. Food and Drug Administration in 2006 and has not yet been as successful as some analysts had predicted.
The first post, found at www.thediabetesblog.com, critiques manufacturer Pfizer’s plan to begin advertising Exubera directly to patients. This blog entry is written by Allie Beatty, a writer with Type 1 diabetes.
The second post, found at www.diabetesmine.com, reports on recent press treatment of Exubera and the opinions of both industry experts and users on the product’s viability. That blog entry is written by Amy Tenderich, a writer with Type 1 diabetes.
This week, we’d like to direct your attention to two blog posts about Exubera, the inhaled insulin product that was approved by the U.S. Food and Drug Administration in 2006 and has not yet been as successful as some analysts had predicted.
The first post, found at www.thediabetesblog.com, critiques manufacturer Pfizer’s plan to begin advertising Exubera directly to patients. This blog entry is written by Allie Beatty, a writer with Type 1 diabetes.
The second post, found at www.diabetesmine.com, reports on recent press treatment of Exubera and the opinions of both industry experts and users on the product’s viability. That blog entry is written by Amy Tenderich, a writer with Type 1 diabetes.
